Sanofi, Merrimack cancer drug flops (again) in second round of PhII program

John Carroll

Seven months after a mid-stage from and Pharmaceuticals flunked its first mid-stage test, researchers are back with another failure to report. The Cambridge, MA-based biotech said that MM-121 (SAR256212), partnered with Sanofi in a $ 530 million deal, failed to hit the primary endpoint on progression free survival for ovarian cancer when combined with Taxol. Once , though, the investigators are pointing to a subpopulation which benefited from the drug.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS